Contract Research & Services
Clinical Trials

Halozyme Ultrafast Insulin Trials in diabetics yield positive data

PBR Staff Writer Published 24 October 2011

Halozyme Therapeutics has announced positive data from two Phase 2 clinical trials of ultrafast PH20 insulin analog formulations in patients with Type 1 and Type 2 diabetes.

One trial was conducted in type 1 diabetes patients and the other in type 2 patients, both of which compared two ultrafast insulin analog products formulated with rHuPH20 (Lispro-PH20 or Aspart-PH20) to an active comparator, Humalog (insulin lispro).

The patients in both the trials received an insulin analog alone and one of the Analog-PH20 treatments for 12 weeks along with basal insulin glargine.

The trials have met the primary endpoint of non-inferiority of HbA1C compared to the insulin analog comparator, with reduced post-prandial glucose excursions in the PH20 insulin analog arms.

The HbA1C test is a blood test which is used to diagnose type 1 and type 2 diabetes.